CITRARO, Rita
 Distribuzione geografica
Continente #
NA - Nord America 4.439
AS - Asia 3.023
EU - Europa 1.820
SA - Sud America 599
AF - Africa 80
OC - Oceania 36
Continente sconosciuto - Info sul continente non disponibili 8
Totale 10.005
Nazione #
US - Stati Uniti d'America 4.203
SG - Singapore 1.275
IT - Italia 849
CN - Cina 662
BR - Brasile 460
VN - Vietnam 284
DE - Germania 272
IN - India 261
CA - Canada 178
GB - Regno Unito 160
BD - Bangladesh 152
FI - Finlandia 146
HK - Hong Kong 126
SE - Svezia 114
NL - Olanda 52
AR - Argentina 46
MX - Messico 37
ID - Indonesia 35
AU - Australia 34
FR - Francia 31
JP - Giappone 29
IQ - Iraq 27
TR - Turchia 27
ES - Italia 26
ZA - Sudafrica 26
RU - Federazione Russa 25
CO - Colombia 22
EC - Ecuador 22
UA - Ucraina 21
PK - Pakistan 18
UZ - Uzbekistan 18
PL - Polonia 16
CL - Cile 15
CZ - Repubblica Ceca 15
SA - Arabia Saudita 15
IL - Israele 14
RO - Romania 13
GR - Grecia 12
PH - Filippine 12
VE - Venezuela 12
IR - Iran 11
EG - Egitto 9
MA - Marocco 9
AT - Austria 8
CH - Svizzera 8
PY - Paraguay 8
KR - Corea 7
MT - Malta 7
PE - Perù 7
AE - Emirati Arabi Uniti 6
BG - Bulgaria 6
HR - Croazia 6
KE - Kenya 6
TN - Tunisia 6
A2 - ???statistics.table.value.countryCode.A2??? 5
DO - Repubblica Dominicana 5
EE - Estonia 5
JO - Giordania 5
KZ - Kazakistan 5
MY - Malesia 5
PT - Portogallo 5
HN - Honduras 4
LT - Lituania 4
NG - Nigeria 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
UY - Uruguay 4
AF - Afghanistan, Repubblica islamica di 3
AO - Angola 3
BO - Bolivia 3
DZ - Algeria 3
ET - Etiopia 3
EU - Europa 3
GA - Gabon 3
IE - Irlanda 3
JM - Giamaica 3
LK - Sri Lanka 3
NP - Nepal 3
SN - Senegal 3
AL - Albania 2
CY - Cipro 2
KG - Kirghizistan 2
KW - Kuwait 2
MD - Moldavia 2
MN - Mongolia 2
NO - Norvegia 2
RS - Serbia 2
SC - Seychelles 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BE - Belgio 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BW - Botswana 1
CR - Costa Rica 1
GD - Grenada 1
GH - Ghana 1
Totale 9.993
Città #
San Jose 729
Singapore 510
Chandler 430
Ashburn 367
Dallas 343
Munich 230
Santa Clara 215
Bengaluru 169
Milan 167
Hefei 166
Beijing 141
Princeton 129
Lawrence 128
Catanzaro 121
Hong Kong 119
Ottawa 100
Ho Chi Minh City 99
Chicago 91
London 91
Wilmington 76
Turku 69
Helsinki 68
New York 64
Los Angeles 55
Hanoi 52
Boardman 48
Des Moines 44
Catania 43
São Paulo 42
Rome 33
Redwood City 31
Orem 29
Brooklyn 26
Montreal 25
Amsterdam 24
Palermo 23
Tokyo 23
Haiphong 21
Shanghai 21
Chennai 18
Atlanta 17
Council Bluffs 17
Florence 17
Rio de Janeiro 17
Guangzhou 16
Johannesburg 16
Tashkent 16
Toronto 16
Da Nang 15
Boston 14
Melbourne 14
Mexico City 14
Naples 14
Norwalk 14
The Dalles 14
Buffalo 13
San Nicola Manfredi 13
Shenzhen 12
Stockholm 12
Warsaw 12
Brasília 11
Olomouc 11
San Francisco 11
Bari 10
Istanbul 10
Messina 10
Phoenix 10
Sydney 10
Aversa 9
Dhaka 9
Prato 9
Riyadh 9
Hải Dương 8
Madrid 8
Padova 8
Pune 8
Salvador 8
West Jordan 8
Ankara 7
Baghdad 7
Belo Horizonte 7
Biên Hòa 7
Bogotá 7
Boydton 7
Bắc Giang 7
Campinas 7
Can Tho 7
Charlotte 7
Columbus 7
Curinga 7
Curitiba 7
Denver 7
Guayaquil 7
Houston 7
Jakarta 7
Newark 7
Nuremberg 7
Porto Alegre 7
Seattle 7
Tel Aviv 7
Totale 5.794
Nome #
Palmitoylethanolamide modulates pentobarbital-evoked hypnotic effect in mice Involvement of allopregnanolone biosynthesis 260
Adverse drug reactions during biologic therapy in inflammatory disease: real life data from the pharmacovigilance project in the Calabria region 248
Early molecular and behavioral response to lipopolysaccharide in the WAG/Rij rat model of absence epilepsy and depressive-like behavior, involves interplay between AMPK, AKT/mTOR pathways and neuroinflammatory cytokine release 148
Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model 140
First evidence of an altered microbiota and intestinal damage and its link to absence epilepsy in a genetic animal model, the WAG/Rij rat 136
Antidepressants but not antipsychotics have antiepileptogenic effects with limited effects on comorbid depressive-like behaviour in the WAG/Rij rat model of absence epilepsy 123
Effects of some neurosteroids injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy 122
Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy 120
Antiabsence effects of carbenoxolone in two genetic animal models of absence epilepsy (WAG/Rij rats and lh/lh mice) 109
Targeting alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy 106
Effects of chronic sodium alendronate on depression and anxiety in a menopausal experimental model 103
A Brain-To-SONAR Electronic Interface to Bypass Peripheral Auditory System in RATS 99
Cerebral small vessel disease predisposes to temporal lobe epilepsy in spontaneously hypertensive rats 91
Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy 89
Audiogenic epileptic DBA/2 mice strain as a model of genetic reflex seizures and SUDEP 88
Amino acid levels in some brain areas of inducible nitric oxide synthase knock out mouse (iNOS(-/-)) before and after pentylenetetrazole kindling 88
Fosinopril and zofenopril, two angiotensin-converting enzyme (ACE) inhibitors, potentiate the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice 86
Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study 86
N-acetylcysteine aggravates seizures while improving depressive-like and cognitive impairment comorbidities in the WAG/Rij rat model of absence epilepsy 86
Evaluation of the effects of liraglutide on the development of epilepsy and behavioural alterations in two animal models of epileptogenesis 85
Increased efficacy of combining prebiotic and postbiotic in mouse models relevant to autism and depression 85
Altered distribution and function of A2A adenosine receptors in the brain of WAG/Rij rats with genetic absence epilepsy, before and after appearance of the disease 84
T-type channel blocking properties and antiabsence activity of two imidazo [1,2-b]pyridazine derivatives structurally related to indomethacin 83
The mTOR signaling pathway and neuronal stem/progenitor cell proliferation in the hippocampus are altered during the development of absence epilepsy in a genetic animal model 80
3D pharmacophore models for 1,2,3,4-tetrahydroisoquinoline derivatives acting as anticonvulsant agents 80
Metabolic and cognitive effects of ranolazine in type 2 diabetes mellitus: Data from an in vivo model 80
IL-6 Receptor Blockade by Tocilizumab Has Anti-absence and Anti-epileptogenic Effects in the WAG/Rij Rat Model of Absence Epilepsy 78
Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity 78
Enhancement of anti-absence effects of ethosuximide by low doses of a noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist in a genetic animal model of absence epilepsy 78
Biologics for Inflammatory Bowel Disease in Clinical Practice: A Calabria (Southern Italy) Prospective Pharmacovigilance Study 75
Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP) 74
Antiepileptogenic effects of Ethosuximide and Levetiracetam in WAG/Rij rats are only temporary 73
Preclinical activity profile of alpha-lactoalbumin, a whey protein rich in tryptophan, in rodent models of seizures and epilepsy 73
Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy 73
Protective activity of α-lactoalbumin (ALAC), a whey protein rich in tryptophan, in rodent models of epileptogenesis. 72
Alpha-lactoalbumin, a whey protein rich in tryptophan, is effective in rodent models of seizures and epileptogenesis 72
Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy 72
Liraglutide prevents cognitive decline in a rat model of streptozotocin-induced diabetes independently from its peripheral metabolic effects 71
CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations 70
Metabolic Alterations Predispose to Seizure Development in High-Fat Diet-Treated Mice: the Role of Metformin 70
Effects of Histone Deacetylase Inhibitors on the Development of Epilepsy and Psychiatric Comorbidity in WAG/Rij Rats 70
Cenobamate enhances the anticonvulsant effect of other antiseizure medications in the DBA/2 mouse model of reflex epilepsy 69
Vasostatin-1 restores autistic disorders in an idiopathic autism model (BTBR T+ Itpr3tf/J mice) by decreasing hippocampal neuroinflammation 68
Assessing Gender Differences in Neuropathic Pain Management: Findings from a Real-Life Clinical Cross-Sectional Observational Study 68
Non-competitive AMPA glutamate receptors antagonism by perampanel as a strategy to counteract hippocampal hyper-excitability and cognitive deficits in cerebral amyloidosis 68
The potential role of cannabinoids in epilepsy treatment. 68
Antiseizure Medications in Alzheimer’s Disease from Preclinical to Clinical Evidence 67
Cognitive impairment in the WAG/Rij rat absence model is secondary to absence seizures and depressive-like behavior 67
Everolimus improves memory and learning while worsening depressive- and anxiety-like behavior in an animal model of depression 67
First evidence of altered microbiota and intestinal damage and their link to absence epilepsy in a genetic animal model, the WAG/Rij rat 67
Huperizine A reduces neuronal loss and enhances brain expression of nerve growth factor and high-affinity receptor TrkA, and reverses memory and cognitive deficits, in rats with excitotoxic lesion of nucleus basalis magnocellularis 66
Pharmacokinetic considerations about antiseizure medications in the elderly 66
Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation  65
A questionnaire-based study on prevalence and treatments of headache in Secondary Schools people of Catanzaro 65
Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures 65
Oleil hydroxytyrosol (Htol) exerts anti-myeloma activity by antagonizing key survival pathways in malignant plasma cells (CO-FIRST AUTHOR) 65
Bioinspired Electric Stimulation: Comparison of ECoG Spectrum in the Main Auditory Structures 64
Long-Term High-Fat Diet Aggravates Absence Seizures and Neurobehavioral Disorders Without Inducing Metabolic Disorders in WAG/Rij Rats: Involvement of Systemic and Central Inflammation 63
Epidemiology and outcomes of status epilepticus 62
Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice 62
Microbiota-gut brain axis involvement in neuropsychiatric disorders 61
Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures. Expert Opin Pharmacother. 2014 Jan 17. [Epub ahead of print] PubMed PMID: 24437529. 61
The Anticonvulsant Activity of a Flavonoid-Rich Extract from Orange Juice Involves both NMDA and GABA-Benzodiazepine Receptor Complexes 60
Intestinal inflammation increases convulsant activity and reduces antiepileptic drug efficacy in a mouse model of epilepsy 60
Antidepressants drugs for seizures and epilepsy: Where do we stand? 59
Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study 59
Antiepileptogenic effects of the selective COX-2 inhibitor etoricoxib, on the development of spontaneous absence seizures in WAG/Rij rats 59
Perampanel effects in the WAG/Rij rat model of epileptogenesis, absence epilepsy, and comorbid depressive-like behavior 58
mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis 58
A Multiple Synergic Treatment for Non-Healing Ulcer Management in a Patient with Klippel–Trenaunay Syndrome 57
Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis 57
Effects of non-competitive AMPA receptor antagonists injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy 57
Development of 3-substituted-1H-indole derivatives as NR2B/NMDA receptor antagonists 57
Nano‐hydrogel embedded with quercetin and oleic acid as a new formulation in the treatment of diabetic foot ulcer: A pilot study 57
Colchicine in Managing Skin Conditions: A Systematic Review 57
An In Vivo Electroencephalographic Analysis of the Effect of Riluzole against Limbic and Absence Seizure and Comparison with Glutamate Antagonists 56
Effect of Statins on Lung Cancer Molecular Pathways: A Possible Therapeutic Role 56
Immediate and controlled-release pregabalin for the treatment of epilepsy 56
Butyrate prevents valproate-induced liver injury: In vitro and in vivo evidence 56
An Open Retrospective Study of a Standardized Cannabidiol Based-Oil in Treatment-Resistant Epilepsy 56
Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study 55
Statins and Epilepsy: Preclinical Studies, Clinical Trials and Statin-Anticonvulsant Drug Interactions 55
Direct Modulation of High-Frequency Neural Oscillations in the Auditory Cortex Through Electrical Microstimulation Generated by PVDF Sensors 55
Oral Metformin Ameliorates Bleomycin-Induced Skin Fibrosis 55
Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study 54
Real-World Safety Profile of Biologics Used in Rheumatology: A Six-Year Observational Pharmacovigilance Study in the Calabria Region 54
Prescribing Pattern and Safety Profile of Biological Agents for Psoriasis in Real-World Practice: A Four-Year Calabrian Pharmacovigilance Analysis 54
Vigabatrin has antiepileptogenic and antidepressant effects in an animal model of epilepsy and depression comorbidity 54
mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy 54
HDL (High-Density Lipoprotein) and ApoA-1 Potentially Modulate Pancreatic α-Cell Glucagon Secretion 54
Glucagon induces the hepatic expression of inflammatory markers in vitro and in vivo 54
Seizure susceptibility to various convulsant stimuli in the BTBR mouse model of autism spectrum disorders 53
Are big potassium-type Ca2+-activated potassium channels a viable target for the treatment of epilepsy? 53
Comparative Analysis of the Treatment of Chronic Antipsychotic Drugs on Epileptic Susceptibility in Genetically Epilepsy-prone Rats 53
Oxygen–Ozone Therapy in Cervicobrachial Pain: A Real-Life Experience 52
Genetically epilepsy-prone rats (GEPRs) and DBA/2 mice: Two animal models of audiogenic reflex epilepsy for the evaluation of new generation AEDs 52
Corrigendum to "Antiabsence effects of carbenoxolone in two genetic animal models of absence epilepsy (WAG/Rij rats and lh/lh mice)" (DOI:10.1016/j.neuropharm.2005.04.012) 52
Synthesis and anticonvulsant evaluation of N-substituted isoquinoline AMPA receptor antagonists 52
Metalloproteases in Pain Generation and Persistence: A Possible Target? 51
Pharmacovigilance in pharmaceutical companies: An overview 51
Totale 7.480
Categoria #
all - tutte 83.893
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 83.893


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 0 0 0 0 0 0 5
2021/2022435 3 6 9 92 21 14 7 84 79 50 58 12
2022/20231.248 263 101 48 109 120 102 15 81 191 86 91 41
2023/2024734 120 90 63 61 54 121 31 46 11 47 29 61
2024/20252.141 262 71 105 90 143 262 161 94 237 71 266 379
2025/20265.148 303 448 556 674 512 244 653 256 636 422 308 136
Totale 10.281